Tracer library / [161Tb]Tb-cAC10
[161Tb]Tb-cAC10
Also written as [Tb-161]Tb-cAC10
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated anti-CD30 monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- CD30, a receptor overexpressed in lymphomas, targeted via anti-CD30 antibody cAC10 PMID 40456588
- Clinical application
- Radioimmunotherapy for CD30-positive lymphomas (preclinical, xenograft mouse model study) PMID 40456588
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >90% | cAC10 antibody conjugated with p-SCN-Bn-DOTA Macrocyclics | 40456588 2025 J Nucl Med Conjugation of the antibody to DOTA was performed by incubation with p-SCN-Bn-DOTA (Macrocyclics). |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Macrocyclics
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [161Tb]Tb-cAC10, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40456588. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40456588: 'cAC10 antibody conjugated with p-SCN-Bn-DOTA'.